FDA officials: ‘Significant work’ still needed for rare disease drug development
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesChemistry, Manufacturing and Controls (CMC)Clinical TrialsNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy